No profile data available.
ALX Oncology Holdings Inc. (ALXO) is a healthcare company in the additional cancer treatment drugs industry, based in South San Francisco, United States, with about 48 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$101.70 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $172.85 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
ALX Oncology reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$172.85 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Adagene Inc. (ADAG), Innate Pharma S.a. (IPHA), Compass Therapeutics, Inc. (CMPX), Kazia Therapeutics Limited (KZIA).